BRD2 and progressive multifocal leukoencephalopathy: In fact, adherence to the risk mitigation plan, early switching of patients at high-risk to other DMTs as well as implementation of extended interval dosing (EID) have contributed to reduce incidence rates of NAT-PML over the last years [30–34].